PASADENA, Calif., Aug. 30, 2016 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-based cancer products using its proprietary technology, today announced the issuance of an additional U.S. patent, U.S. Patent No. 9,428,553, entitled "Meditopes and Meditope-Binding Antibodies and Uses Thereof."
"We are excited by the continued momentum represented by this new U.S. patent, along with other recently-issued foreign patents. In addition to strengthening our intellectual property, it differentiates our novel antibody technology platform and validates the breadth of potential applications for our SnAP technology," said Stephanie Hsieh, Meditope's president and chief executive officer. "We believe these many potential applications of SnAP technology offer very compelling opportunities for the industry today, and we look forward to advancing our internal pipeline, while continuing to pursue partnership opportunities."
Meditope Biosciences now has eight issued patents worldwide related to its technology platform, including three in the United States.
About Meditope Biosciences, Inc.
Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (Site-specific novel Antibody Platform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP has the potential of turning any antibody into a proprietary, site-specific "LEGO-like" system that is able to attach and detach nearly anything to an antibody. Meditope's SnAP technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. Visit www.meditope.com.
SOURCE Meditope Biosciences, Inc.